Supplemental Table 1.
Patient Characteristics of the Screened Population
| Included Patients (N = 92) | Excluded Patients (N = 58) | |
|---|---|---|
| Clinico-pathologic characteristics | ||
| Median age, y (range) | 64.5 (37-87) | 69 (33-87) |
| Female gender | 44 (48) | 31 (53) |
| Smoking status, ever | 84 (91) | 52 (90) |
| ECOG PS | ||
| 0-1 | 75 (82) | 27 (47) |
| ≥2 | 17 (18) | 28 (48) |
| Not reported | 0 (0) | 3 (5) |
| Histology | ||
| Non-squamous | 70 (76) | 45 (78) |
| Squamous | 15 (16) | 9 (15) |
| Poorly differentiated | 7 (8) | 4 (7) |
| Driver mutation | ||
| KRAS | 33 (36) | 19 (33) |
| EGFR | 6 (7) | 3 (5) |
| Others | 3 (3) | 3 (5) |
| None identified | 40 (43) | 25 (43) |
| Not assessed | 10 (11) | 8 (14) |
| PD-L1 TPS, % | ||
| <1 | 24 (26) | 8 (14) |
| 1-49 | 17 (18) | 15 (26) |
| ≥50 | 42 (46) | 31 (53) |
| Not assessed | 9 (10) | 4 (7) |
| TMB, mut/mB | ||
| <10 | 20 (22) | 14 (24) |
| ≥10 | 30 (32) | 11 (19) |
| Not assessed | 42 (46) | 33 (57) |
| Treatment characteristics | ||
| Line of pembrolizumab | ||
| First line | 65 (71) | 39 (67) |
| ≥Second line | 27 (29) | 19 (33) |
| Treatment | ||
| Monotherapy | 41 (45) | 35 (60) |
| With chemotherapy | 51 (55) | 22 (38) |
| Not known | 0 (0) | 1 (2) |
| Treatment center | ||
| BIDMC | 47 (51) | 34 (59) |
| VMC | 45 (49) | 24 (41) |
| Median no. treatment cycles (range) | 8 (4-41) | 2 (1-3) |
| Any grade irAE, yes | 54 (59) | 16 (28) |
| ≥Grade 3 irAE, yes | 28 (30) | 12 (21) |
| Systemic immunosuppression for irAE, yes | 41 (45) | 16 (28) |
Abbreviations: BIDMC = Beth Israel Deaconess Medical Center; CR = complete response; ECOG = Eastern Cooperative Oncology Group; irAE = immune-related adverse events; PD-L1 = programmed death-ligand 1; PS = performance status; TMB = tumor mutational burden; TPS = tumor proportion score; VMC = Vidant Medical Center.
Data shown as n (%), unless specified.